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ABSTRACT 
 
The hepatitis B virus remains a major public health problem even after decades of its 
discovery.  Horizontal transmission during early childhood is the predominant mode of 
transmission in highly endemic regions such as sub-Saharan Africa.  Infection exhibits a 
wide spectrum of clinical manifestations, from an asymptomatic stage to severe liver 
disease which may result in hepatocellular carcinoma (HCC).   
 
The HBV X protein (HBx) has been implicated in carcinogenesis, which often has a poor 
prognosis, consequently the use of highly specific monoclonal antibodies (mAbs) directed 
against HBx in an enzyme-linked immunosorbent assay (ELISA) could lead to early 
identification of HBV carriers at risk of developing liver cancer.   
 
A variety of mixed hybridoma cell cultures secreting anti-HBx antibodies were cloned and 
sub-cloned by “limiting dilution”.  Clonal supernatants were assessed for anti-HBx 
antibody production by Indirect ELISA and Western/Immunoblotting.  Monoclonal 
antibodies were then characterized according to their relative binding affinity (Indirect 
ELISA) and relative epitope specificity (Competitive ELISA).  One of our monoclonal 
antibodies was found to bind to the same epitope on HBx as the commercial anti-HBx 
antibody and with the same high affinity. 
 
In the developed Sandwich ELISA, our monoclonal antibody proved effective as the 
„detecting‟ antibody when the commercial anti-HBx antibody was deployed as the 
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„capture‟ antibody.  This Sandwich ELISA will be further developed in our laboratory with 
the object of applying it to patient sera. 
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Chapter 1: INTRODUCTION 
 
The hepatitis B virus (HBV) is classified in the Hepadnaviridae family.  Infection-
susceptible mammals include humans and chimpanzees, although mammals such as 
ground squirrels, woodchucks as well as a range of bird species are prone to infection by 
hepadnaviruses similar to HBV, namely: ground squirrel hepatitis virus (GSHV), 
woodchuck hepatitis virus (WHV) and duck hepatitis B virus (DHBV), respectively 
(Miller & Robinson, 1986; MacDonald, et al., 2000; Dandri et al., 2005).  Interestingly, 
HBV has been found to have a common evolutionary origin with retroviruses, sharing the 
property of encoding a reverse transcriptase and replicating via an RNA-to-DNA step 
(Miller & Robinson, 1986; Strauss & Strauss, 2002).  While safe and effective vaccines 
have been available since 1981, more than 350 million adults are chronically infected with 
HBV, of which approximately 90 % recover and develop protective antibodies against 
future infections (Wieland & Chisari, 2005; Wasley et al., 2008; 
http://www.hepb.org/hepb/statistics.htm).   
 
HBV is highly endemic in Asia and Africa and it is estimated that one million people die 
each year from HBV and its complications (http://www.hepb.org/hepb/statistics.htm).  
Infection is further compounded, in Africa, by the contamination of staple crops through 
exposure to aflatoxin (Hainaut & Boyle, 2008).  The virus is transmitted by the exchange 
of infected body fluids e.g. blood, vaginal secretions, semen and a case of transmission 
through saliva has been reported (van der Eijk et al., 2004; Hui et al., 2005; 
http://ww.cdc.gov/hepatitis/HBV/HBVfaq.htm#b1).  Healthcare workers and individuals 
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living in close contact with an infected person are at a high risk of being infected (Wasley 
et al., 2008).  All known hepadnaviruses are hepatotropic i.e. infect liver cells and can all 
cause hepatitis in their host (Strauss & Strauss, 2002; Wieland & Chisari, 2005).   Once 
infected, initial symptoms may include fatigue, fever and mild nausea 
(http://www.cdc.gov/hepatitis/B/bFAQ.htm#symptoms).  As the disease develops, jaundice 
and liver enlargement may ensue.  While most patients recover and become immune to the 
virus, it is (clinically) estimated that 5 – 10 % of infected adults will develop chronic 
hepatitis and will be at high risk of developing hepatocellular carcinoma (Hwang et al., 
2003). 
 
1.1 DISCOVERY OF HBV 
 
The path to the discovery of HBV began in 1965 when Dr Baruch Blumberg and a team of 
researchers observed a precipitin reaction between the sera of an Australian aborigine and 
a transfused haemophiliac from the United States of America (Blumberg, 2003).  The 
lipoprotein responsible for the reaction, also known as the „Australia antigen‟, was found 
to be present at a higher frequency in sera of hepatitis patients than in control subjects 
(McLachlan, 1991).   This led the researchers to propose that this antigen may be involved 
in the occurrence of viral hepatitis (Prince, 1968).  Through electron microscopy several 
particles were observed and, based on morphology, it was suggested a 42 nm Dane particle 
represented the infectious agent (Dane et al., 1970; Cossart, 1971).  Further analysis of the 
structures allowed for biochemical and physical characterization of the components which 
then led to the discovery of the other antigens (McLachlan, 1991).   
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Dr. Blumberg was awarded the Nobel Prize in Medicine for his discovery of the hepatitis B 
virus in 1976 (http://www.hepb.org/about/blumberg.htm). 
 
1.2 GENOMIC STRUCTURE OF HBV  
 
The viral genome is a partially double-stranded circular molecule of approximately 3200 
base pairs.  The small genome comprises four overlapping open reading frames (ORFs) 
encoding the surface, core, polymerase and X proteins (Araki et al., 1989), which are 
essential for the viral life cycle (Blum et al., 1992) (Figure 1.1).   
 
Translation of the S gene results in three surface proteins (small, middle and large) which 
only differ at the N termini (Imamura et al., 1987; Dalgleish & Weiss, 1999).  The pre-
core/core ORF contains two start codons coding for two overlapping proteins, the e 
(HBeAg) and core (HBcAg) antigens.  The core protein is produced when translation 
begins at the second AUG start codon.  Translation from the first start codon results in the 
formation of the pre-core protein which then undergoes post translational modification to 
yield the HBeAg (Roossinck & Siddiqui, 1987).  The HBeAg has not been well 
characterized chemically but has been shown to play an important role in the interaction of 
the virus with the immune system (Alter et al., 1976; Neurath & Strick, 1977; Baumert et 
al., 2007).  The DNA polymerase is encoded for by the P ORF and allows replication by 
reverse transcription (Anzola, 2004). 
 
However, all known hepadnaviruses encode the X protein (HBx) (Reifenberg et al., 2002). 
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Figure 1.1:  A representation of the gene organization of the HBV genome.  HBV 
DNA was obtained from a genotype A virus (Arbuthnot et al., 2007).  The HBV genome is 
a double-stranded circular DNA containing four open reading frames coding for 
polymerase (P), surface antigens (preS1, preS2 and S), precore (preC), core (C) and X.  
cis-elements that regulate HBV transcription are indicated by the circular and rectangular 
symbols. 
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Although its function has not been completely elucidated, this protein has been shown to 
be involved in carcinogenesis as it induces liver cancer in transgenic mice (Will, 1991; 
Blum et al., 1992).  Of the HBV proteins, HBx is one of the most intensely studied.  
 
1.3 HBV X PROTEIN  
 
The hepatitis B virus x gene is the smallest, with a length of 465 nucleotides and is 
conserved among mammalian hepadnaviruses (Murakami, 1999).  The structural gene first 
identified by Galibert et al. has the potential to produce a protein of between 145 – 154 
amino acids (Galibert et al., 1982; Tiollas et al., 1985; Feitelson, 1986) that has been 
shown to require an enhancer element for maximal activity (Treinin & Laub, 1987; 
Dalgleish & Weiss, 1999).  It has been generally reported that the x gene produces a ~ 17 
kDa protein, but research at The Fox Chase Cancer Center showed that some sera from 
HBV-infected patients contained another polypeptide species of ~ 13 kDa in size 
(Feitelson & Clayton, 1990).  Despite the various sizes of HBx reported, the ORF-encoded 
protein is ~ 17 kDa.  The role of the HBx protein in the viral life cycle and in the 
pathogenesis of HBV infection has been studied extensively.  The strict conservation of the 
X ORF strongly suggests that the protein plays an important role in the viral life cycle 
(Reifenberg et al., 2002). 
 
A large portion of the current knowledge of HBV comes from the study of parallel animal 
hepatitis virus models (Marion et al., 1986; Lambert et al., 1991; Dandri et al., 2005).  
This is because difficulties, such as maintaining functional infected hepatocytes, arise 
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when propagating virus in tissue culture, making the system inappropriate for investigating 
the mechanism of infection (Gripon et al., 1993; Sprinzl et al., 2001).  Infecting 
woodchucks with WHV has proved to be an outstanding model for researching HBV 
infection in humans (Chen et al., 1993; Gouillat et al., 1997; Tennant et al., 2008).  Studies 
in this model have demonstrated that HBx is required for the establishment of infection in 
vivo (Zoulim et al., 1994; Seeger & Mason, 2000) but is dispensable for viral DNA 
synthesis in transfected tissue culture cells (Blum et al., 1992; Seeger & Mason, 2000; 
Reifenberg et al., 2002).  HBx has been shown to trans-activate the transcription of a wide 
range of viral and cellular genes (Colgrove et al., 1989).  It has been speculated that the 
activation of the HBV enhancer by HBx may be required for viral replication (Shaul et al., 
1985; Spandau & Lee, 1988).  The mechanism by which the activation occurs is unknown, 
but it is thought the protein may bind to or recruit other proteins to the enhancer, thus 
activating it (Spandau & Lee, 1988).  While being dispensable in vitro, HBx supports viral 
DNA transcription through its functional similarity to nucleotide diphosphate kinases (De-
Medina & Shaul, 1994).  
 
Sequence homology among mammalian hepadnaviruses was used to subdivide HBx into 
regions, and it was found that the middle region is involved in signal transduction (Nijhara 
et al., 2001).  The highly conserved N-terminal region was found to have a negative 
regulatory function and is dispensable for trans-activation (See Figure 1.2) (Misra et al., 
2004).  The carboxy-terminal plays a crucial role in the trans-activation function of 
HBx(Reddi et al., 2003).  Furthermore, transfecting animals with HBx truncated at the C-
terminal causes them to be serologically negative for at least 24 weeks (Chen et al., 1993).   
Introduction  7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Schematic representation of the HBV X ORF gene product showing the N and C termini (Adapted from Colgrove et 
al., 1989; McLachlan, 1991).  The amino acid positions are represented by the scale above. 
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HBx is rapidly degraded by a cellular 26S complex through ubiquitination, resulting in low 
intracellular levels of HBx (Kim et al., 2008).  It has also been shown that ubiquitination-
independent proteolysis can occur (Hershko & Ciechanover, 1998; Orlowski & Wilk, 
2003).  In vivo HBx functions as both the substrate and inhibitor of the proteasome 
complex (Hu et al., 1999).  Kim et al. have shown that the middle and carboxy-terminal 
domains of HBx play a role in its degradation while the amino-terminal was shown to have 
little effect on the protein‟s stability (Kim et al., 2008).  In the same study, proteasome 
inhibitors hindered this degradation but also blocked the trans-activation function of HBx.  
 
1.3.1 Localisation 
 
Knowledge of hepatitis B antigens to date has been made possible through the 
development of sensitive radioimmunoassay and immunofluorescence techniques for their 
detection in serum and tissue, respectively (Berquist et al., 1975).  HBx variants have been 
found integrated in host chromosomes as well as being expressed in HCC tissues (Chen et 
al., 2000).  Many debates have arisen regarding the sub-cellular localisation of the X 
protein, but it is generally agreed that the protein predominantly localises in the nucleus 
(Su et al., 1998; Henkler et al., 2001); however, accumulation in the cytoplasm and 
association with cytoskeletal components has also been observed (Siddiqui et al., 1987; 
Zentgraf et al., 1990; Su et al., 1998; Henkler et al., 2001).   
 
Cytoplasmic HBx is found with dispersed and sometimes punctate distribution 
(McLachlan, 1991).  An extensive association of HBx with mitochondria has been 
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observed, but no association with the endoplasmic reticulum, lysosomes or the plasma 
membrane (Henkler et al., 2001).  From the cytoplasm, HBx is transferred to the nucleus 
through interaction with trafficking proteins (Murakami et al., 2001).  Interaction of HBx 
with a mitochondrial anion channel may cause the loss of mitochondrial membrane 
potential, thus inducing mitochondria-dependent cell death (Rahmani et al., 2000; Chami 
et al., 2003).  This was observed at high levels of HBx expression involving clumping and 
organelle aggregation leading to abnormal mitochondrial distribution (Henkler et al., 
2001).  Expression of HBx may also induce apoptosis which has, likewise, been associated 
with mitochondrial membrane alterations (Terradillos et al., 2002). 
 
1.3.2 Pathways disrupted 
 
HBx has been shown to induce HCC through a variety of mechanisms such as 
transcriptional activation (Murakami et al., 2001; Carretero et al., 2002), signalling 
cascades, DNA repair, p53 expression and telomere dynamics. 
 
HBx is implicated in activating cell pathways such as the mitogen-activated protein kinase 
(MAPK) pathway which plays an important role in tumour promotion (Kekulé et al., 1993; 
reviewed in Arbuthnot et al., 2000).  The NF-kB pathway may also undergo stimulation by 
HBx thus conferring resistance of virus-infected cells to anti-Fas killing (Pan et al., 2001).  
In a study by Lucito & Schneider, the X protein was able to achieve maximal activation of 
NF-kB independently of the protein kinase C (PKC) system (Lucito & Schneider, 1992).  
Furthermore, HBx disrupts the first step of nucleotide excision repair (NER) thus 
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preventing the recognition of DNA damage which contributes to carcinogenesis (Becker et 
al., 1998).  p53, a tumour suppressor protein, normally causes cell cycle arrest in response 
to DNA damage (reviewed in Prives & Manfredi, 1993).  It has been shown through 
affinity chromatography that, during infection, HBx directly binds p53 thus inhibiting it, 
further promoting carcinogenesis (Truant et al., 1995; Feitelson, 1998; Murakami et al., 
2001). 
 
Progressive shortening of telomeres has been shown to occur during hepatocellular 
carcinoma, compounding the normal telomere length loss occurring in normal somatic 
cells (Miura et al., 1997).  This in turn leads to the activation of human telomerase reverse 
transcriptase (hTERT), the expression and activity of which has been shown to be 
upregulated by the HBx antigen (HBxAg) (Zhang et al., 2005).  hTERT adds repeated 
telomere sequences onto the end of chromosomes, thus stabilizing telomere length in 
immortal cells (Tian et al., 2009).  hTERT and HBxAg expression was observed in all 
cirrhotic tissues and 67.6 % and 76.5 % in tumour samples, respectively (Zhang et al., 
2005).  This relationship may be a useful marker for the early detection of disease 
progression in liver disease (Miura et al., 1997). 
 
1.3.3 The X protein and disease progression 
 
Hepatocellular carcinoma is a common tumour worldwide, typically developing in patients 
with chronic liver disease and cirrhosis (Chen et al., 2000; Lian et al., 2003).  The 
development of fibrosis is an important factor in disease progression in HBV patients 
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(Norton et al., 2004).  Fibrosis is characterized by an enhanced synthesis of the 
extracellular matrix (ECM) attributable to the altered expression of its genes.  HBx has 
been identified as a culprit, activating NF-kB, thus trans-activating the fibronectin 
promoter leading to excessive amounts of ECM (Norton et al., 2004). 
 
HCC appears in the liver, arising from the hepatic parenchymal cells (Schafer & Sorrell, 
1999).  The molecular pathways of HBV-mediated HCC have not been well characterized, 
but in most HCCs, integration of the HBV DNA into the host genome occurs, thus 
inducing chromosome instability (Chen et al., 2000).  This then leads to insertional 
mutations which then activate endogenous genes such as those involved in cell 
proliferation (Pang et al., 2006).  Expression of viral proteins, such as HBx, then alters 
various pathways, leading to carcinogenesis. 
 
HBx, in particular, plays an important role in the development of HBV-related HCC 
(Koike, 1995).  HBx has been previously described as an activator of a variety of pathways 
such as the lipogenic pathway (Yamashita et al., 2009).  This activation is brought about 
indirectly through the activation of the MAPK pathway which, in turn, causes an 
upregulation of sterol regulatory element binding factor 1 (SREBF 1).  Activation of this 
pathway has been identified as a key feature in the development of cancer and the poor 
prognosis of HCC (Yamashita et al., 2009).  HCC with elevated levels of SREBF1 was 
also found to correlate with a high mortality rate.   
 
Research has also been conducted to identify the natural effectors of the HBV X protein.  
In HBx positive HepG2 cells, two groups identified the upregulated genes to be URG11 
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and URG4, respectively (Tufan et al., 2002; Lian et al., 2003).  Both genes were found to 
accelerate tumour formation and stimulate hepatocellular growth.  URG4 was weakly 
expressed in uninfected liver but the opposite was found in HBV-infected liver and HCC 
cells.  Upregulation of URG11 also contributed to the production of larger tumours in 
SCID mice (Tufan et al., 2002; Lian et al., 2003). 
 
Lian et al. also studied differentially expressed genes in HBx positive and negative cells 
(Lian et al., 1999).  The human homologue of sui1 (hu-sui1), that encodes a translation 
initiation factor, was found to be suppressed in HBx positive HepG2 cells.  Hu-sui1 was 
expressed in non-tumour liver cells, thus appearing to be negatively regulating cell growth 
in HCCs. 
 
It has been suggested that the ingestion of chemical carcinogens from food is required 
before HCC develops in the liver (Kasai et al., 1996).  One such carcinogen, aflatoxin, is 
an important environmental contaminant which contributes to the high incidence of HCC 
in Asia and Africa (Liu et al., 2008).  Alcohol consumption and underlying liver disease 
can also contribute to the increasing mortality rate of HCC patients (Marrero et al., 2005).  
Usually, HCC has a poor prognosis; therefore, markers are required to determine disease 
progression, allowing for the treatment of patients before the disease becomes too severe. 
 
In a review conducted by Wright et al., a wide variety of serum markers was identified but 
were said to lack specificity and sensitivity (Wright et al., 2007).  They include, among 
others, HBx, alpha-fetoprotein (AFP), serum albumin, hepatocyte and insulin growth 
factors (Stuart et al., 1996; Wright et al., 2007).  In several studies conducted in patients 
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with HBV-associated HCC, staining patterns of the HBx protein were analyzed in tumour 
and non-tumour liver sections (Wang et al., 1991; Pál et al., 2001; Zhu et al., 2006).  HBx 
was found to be the most prevalent marker and its expression during chronic infection 
could help in determining progression to HCC.  Liver tissue samples from HCC and 
chronic hepatitis patients were treated with an anti-HBx antibody by Hwang et al. in a 
study conducted in 2003.  Reactive antigen was detected in 80% of HCC liver samples and 
30% of chronic hepatitis liver samples (Zentgraf et al., 1990; Hwang et al., 2003).  This 
evidence strongly suggests that HBx may be an important prognostic marker for the 
development of HCC.   
 
Anti-HBx antibody was also found in significantly higher levels in the sera of HCC 
patients than in chronically infected patients and healthy individuals (Hwang et al., 2003; 
Zhang et al., 2006).  The level of this antibody (Ab) has been found to be lower in acutely 
infected individuals, being only detected in 5 out of 17 patients (Abraham et al., 1989).  
This strongly suggests that both the qualitative and quantitative analyses of HBx are 
important in prognosis, and that the anti-HBx Ab might be used as a prognostic marker as 
well.   
 
1.4 THE HEPATITIS B VIRUS (HBV) IN AFRICA 
 
The world is divided into regions of high, intermediate and low HBV endemicity.  Most 
countries in Africa have high endemicity, with chronic infection rates of 7 – 26 % (West 
and sub-Saharan Africa) and 6.5 – 7.5 % (Central and Southern Africa) (André, 2000).   
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Previously, Asia was also classified as an area of high endemicity, but this has changed 
due to the introduction of successful vaccination programme.  China now remains the only 
country in this category, with a 7 – 20 % prevalence of HBV surface antigen (André, 
2000).  Approximately, more than 75 % of the world‟s HBV chronic carriers are located in 
Asia (Maynard, 1990).   
 
The second highest proportion of chronic carriers is located in sub-Saharan Africa where 
financial resources and adequate healthcare systems are very limited (Maynard, 1990).  In 
1985 it was reported that 230 000 children would die due to long-term complications of 
HBV infection, out of a total of 19.4 million births in Africa (Maynard, 1990).  In the 
period between 1998 to 2007, 2 077 cases of HBV infection were reported in South Africa, 
however these numbers do not represent true incidence due to under-reporting, among 
other reasons (Department of Health – South Africa, 2008). 
 
The main mode of transmission in Asia and Africa is horizontal transmission, where virus 
is transmitted between children (under 5 years of age) especially in crèches and children 
homes (Toukan & the Middle East Regional Study Group, 1990).  Young HBV carriers 
have a higher frequency of HBeAg positivity than older carriers, thus suggesting the 
younger carriers are a likely source of infection (Kiire, 1990; Toukan & the Middle East 
Regional Study Group, 1990).  Living in large families, often sharing eating and cleaning 
utensils (may be source of infected serum and blood); intrafamilial contact due to cultural 
habits and a poor socioeconomic status are contributing factors to the prevalence of the 
HBV carrier state (Toukan et al., 1990). 
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It has been estimated that HBV infection is the cause of acute hepatitis in 40 % of 
hospitalized patients in Algeria (Nouasria et al., 1984).  The HBV-related hepatitis delta 
virus (HDV) has also been implicated in the increased disease burden in Africa and the 
Middle East.  Algeria, among other countries, reported increased levels of HDV to be 
associated with chronic liver disease (Toukan & the Middle East Regional Study Group, 
1990).  However, the prevalence rates of these two viruses were not found to parallel each 
other on a wider global scale (Toukan & the Middle East Regional Study Group, 1990). 
 
The global control and prevention of HBV infection has involved the incorporation of 
HBV mass immunisation into the Expanded Programme of Immunisation.  This is true for 
countries whose carrier rate exceed 2.5 % but is limited as the country needs to possess the 
financial means to purchase the vaccine (Maynard, 1990).  The mode of transmission, 
correlating with age, needs to be taken into consideration as the high risk groups need first 
preference when vaccinating. 
 
Universal immunisation began in 1995 in South Africa, giving infants three doses of 
vaccine at six, ten and fourteen weeks of age (François et al., 2008).  This can prove 
difficult in most countries in Africa as most babies requiring vaccination only get 
introduced to the healthcare system at approximately three months due to being born at 
home and at rural areas (Maynard, 1990).  This makes the rapid delivery of the first dose of 
vaccine very difficult. 
 
With all this said on preventative measures, focus is also placed on efficient and effective 
diagnostic strategies in order to delay disease progression, thus aiding in the reduction of  
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the number of deaths occurring due to the hepatitis B virus.   
 
The use of antibody technology, specifically monoclonal antibodies, in the detection of 
HBx would allow for the rapid and specific detection of this antigen in patient sera and 
liver samples.  Early detection of which is crucial in the prognosis of HCC.   
 
1.5 MONOCLONAL ANTIBODIES  
 
Monoclonal antibodies are specialized glycoproteins, immunoglobulins (Igs), which are 
produced by B-lymphocytes (See Figure 1.3) (Milstein, 1980; Liddell & Cryer, 1991).  
These antibodies differ from antibodies in general, in that they are produced from a single 
clone of B lymphoid cells (tumours of an antibody-producing cell) (Mayer & Walker, 
1987).  B-lymphocytes are short-lived but can be „immortalized‟ by fusion with a myeloma 
cell line to produce a hybridoma.  Antibody-secreting hybridomas were first generated by 
Köhler & Milstein for which they were awarded the Nobel Prize.  The development of 
monoclonal antibodies in biological research has, ever since, increased exponentially 
(Köhler & Milstein, 1975, 1976; Liddell & Cryer, 1991). 
 
Previously, hybridomas derived from myelomas produced the Ig of the myeloma parent as 
well as the antigen-specific antibody of the spleen cell parent (Shulman et al., 1978).  
Hybridomas making only the desired specific antibodies are obtained by fusing 
splenocytes with a tumour cell fusion partner that does not produce Ig itself.  Cell lines  
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Figure 1.3: A schematic diagram of the structural components of an immunoglobulin 
G (IgG) molecule (Crowther, 1995).  Antibodies utilized in this research were monoclonal 
antibodies.  The paratope indicated by the black arrows is the site at which the antibody 
interacts with the antigen epitope.  The Fc region is the portion of the antibody which the 
secondary antibody binds to in an ELISA or Immunoblot. 
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extensively used in research include: Sp2/O-Ag 14 and P3-X63-Ag8 (Shulman et al., 1978; 
Kearney et al., 1979), which were used in this research project. 
 
The generation of Abs to HBx is bedevilled by weak immunogenicity of the viral protein 
(Park et al., 2000; Pál et al., 2003).  However, HBxAg remains the most expressed antigen 
in late stage disease and its detection should, at least, have prognostic value (Pfaff et al., 
1987; Pál et al., 2001). 
 
1.6 DIAGNOSIS AND TREATMENT 
 
1.6.1 Diagnosis  
 
In diagnosing viral hepatitis, it must first be differentiated from other disorders causing 
similar symptoms; standard liver function tests (serum aminotransferases, bilirubin and 
alkaline phosphatase) are performed first (Beers et al., 2006).  Acute viral hepatitis is 
typically associated with alanine aminotransferase (ALT) levels higher than those of 
aspartate aminotransferase (AST); alcoholic hepatitis typically features higher AST levels 
(Matloff et al., 1980).  ALT and AST are transaminase enzymes which are associated with 
liver parenchymal cells and their serum concentration is elevated in acute liver damage 
(Huang et al., 2006).  Viral DNA detection by polymerase chain reaction (PCR) is the most 
accurate diagnostic tool for HBV (Balderas-Renteria et al., 2002).  However, the outcome 
of infection is determined by the interplay of viral replication and the host‟s immune 
system; therefore diagnosis, in clinical practice, involves the detection of viral protein 
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products and host-produced antibodies through serology (Tsitsilonis et al., 2004).  ELISAs 
are used to detect these diagnostic markers (Hwang et al., 2003; Tsitsilonis et al., 2004). 
 
The main hepatitis B-related viral markers are: HBV surface antigen (HBsAg), HBV e 
antigen (HBeAg), antibodies to HBsAg (anti-HBs), antibody to HBeAg (anti-HBe) and the 
antibody to the HBV core antigen (anti-HBc) (Keeffe et al., 2008).  HBsAg is a diagnostic 
marker, which shows infectivity of the blood, and can be detected from the first week of 
infection (Zoulim et al., 1992).  If viral replication is elevated, the HBeAg can also be 
detected in the serum, suggesting increased infectivity (Beers et al., 2006).  This antigen is 
usually present at low levels and has been detected in 30 % of HBsAg positive patients 
(New Zealand National Eye Bank Quality Manual, 2001).  HBeAg is considered a better 
marker of viral infection (as its level aids in the characterization of viral replication and 
infectivity) (Tsitsilonis et al., 2004).  In approximately 90 % of acutely infected adults, 
both antigens are cleared from the system by an effective T cell response, and their 
corresponding antibodies are then produced (New Zealand National Eye Bank Quality 
Manual, 2001).  Antibody levels persist in the blood even after recovery and their detection 
indicates past HBV infection and relative immunity (Beers et al., 2006).   Anti-HBs is the 
best serological indicator of recovery (Raimondo et al., 2003).  This Ab is only detectable 
in patients once they recover from infection, thereafter, having lifelong immunity from re-
infection (New Zealand National Eye Bank Quality Manual, 2001; Wei et al., 2002).  
 
Acute infection lasts approximately two to four weeks and does not require specific 
treatment because more than 90 % of adults spontaneously clear the infection (Gitlin, 
1997; Rizzetto & Ciancio, 2008).  On the other hand, perinataly acquired infection may 
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last for decades with ~ 5 % of patients progressing to cirrhosis (Rizzetto & Ciancio, 2008).  
Risk is further increased in HBeAg positive mothers (Plitt et al., 2007). 
 
Persistence of HBsAg and HBeAg in serum for more than twenty weeks increases the risk 
of progressing to chronic infection (Gitlin, 1997).  Anti-HBc appears at the onset of 
clinical illness and can sometimes be the only marker detected during HBsAg 
seroconversion when HBsAg levels are below the sensitivity threshold of diagnostic tests 
(Holland, 1994; Rizzetto & Ciancio, 2008).  The Ab is mainly found as immunoglobulin M 
(IgM) in acute infection, subsequently switching to IgG, which dominates in chronic 
infection (Gitlin, 1997).  Low levels of anti-HBc (IgM) have been associated with liver 
disease (Zoulim et al., 1992). 
 
A „chronic HBV carrier‟ refers to a person with persistent levels of HBsAg, testing 
positive for more than six months (Rosenthal, 2006).  This type of infection occurs in ~ 10 
% of acutely infected adults or if infection took place at birth or in infancy (New Zealand 
National Eye Bank Quality Manual, 2001).  This type of infection may last a lifetime, 
duration correlating with the risk of developing cirrhosis and HCC (Rizzetto & Ciancio, 
2008).  The HBeAg and anti-HBc (IgG) are also detected in patient sera (Rizzetto & 
Ciancio, 2008).  The presence of HBeAg suggests increased viral replication, therefore 
increased infectivity (Beers et al., 2006).  
 
HBV DNA is detected in the serum of patients with active HBV infection (Keeffe et al., 
2008).  Its detection and quantification also play a role in diagnosis and may provide 
insight into the severity of disease and therefore its prognosis (Rizzetto & Ciancio, 2008).  
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In some cases, DNA detection may be the only indication of infection (occult infection) 
(Carman et al., 1989).  Carriers with active replication are at risk of developing cirrhosis, 
which often leads to HCC (Rizzetto & Ciancio, 2008).  On the other hand, inactive carriers 
may ultimately clear the infection from the blood, but remain occult carriers of HBV in the 
liver (Rizzetto & Ciancio, 2008).  
 
An interesting question to ask would be: “What role does the HBV X protein play in the 
diagnosis and prognosis of HCC?”  Disease stage at the time of HCC diagnosis greatly 
affects the prognosis; clearly rapid, specific and sensitive diagnostic assays are required to 
minimise this problem (Bachtiar et al., 2009).   
 
N-glycan fingerprinting has recently been adapted as a tool for diagnosing HCC in 
cirrhotic patients (Liu et al., 2007; Valerie et al., 2009).  The blood test, known as the 
GlycoHCCTest, measures the concentration and log ratio of two glycans associated with 
tumourogenesis.  In the glycosylation pathway, sugar chains can be altered, depending on 
the physiological condition of the cell; therefore; the type of glycan produced reflects the 
physiological state of a cell (Valerie et al., 2009).  Branch alpha (1,3)-fucosylated 
triantennary glycan was found more abundant in HCC patients whereas the bisecting core 
alpha (1,6)-fucosylated biantennary glycan was elevated in cirrhotic patients.  HCC has 
also been diagnosed by alpha-fetoprotein (AFP) analysis, through ultrasonography, 
computed tomography and histology (Valerie et al., 2009).  AFP is normally produced by 
the embryonic liver cells and is measured as a biomarker to detect a subset of tumours 
(França et al., 2004).  Studies have shown that a mild elevation of AFP occurs in patients 
with cirrhosis; therefore AFP analysis alone is not a reliable test for HCC diagnosis and 
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should be used in conjunction with other tests (Colli et al., 2006).  Apart from being 
expressed mildly in cirrhosis, AFP has been shown to be expressed at higher than normal 
levels in patients with high regenerative activity, without them even having HCC (Nomura 
et al., 1989).   
 
AFP analysis is limited as it cannot be used as the sole test for HCC and is not useful for its 
early detection due to its poor sensitivity (França et al., 2004; Marrero & Lok, 2004).  
Instead, AFP levels are used to monitor treatment, as a decrease in AFP concentration 
correlates with a decrease in tumour growth (Yang et al., 2008).  When screening for HCC, 
blood AFP levels are tested every six months, with ultrasound performed on the liver at 
least once a year (http://www.hepb.org/professionals/hepb_and_liver_cancer.htm).  HCC is 
diagnosed when AFP levels are greater than or equal to 500 ng/ml (Diamandis et al., 
2002). 
 
Early detection of HCC is key in order to offer the possibility of curative treatment 
(Marrero & Lok, 2004), which this study aims to achieve through the use of the HBV X 
protein as the marker for the detection and screening of HCC. 
 
1.6.2 Treatment 
 
Patients with active infection (infection currently producing symptoms) are the most in 
need of treatment, which is primarily aimed at controlling HBV replication and inducing 
remission of liver disease (Mangia et al., 2008).  Through remission, cirrhosis and HCC 
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could be prevented (Liaw, 2005).  One of the indicators for therapy is the persistence of 
HBeAg and HBV DNA for approximately six months as well as the elevation of 
aminotransferases (Hoofnagle & di Bisceglie, 1997).  Treatment options for HCC are 
selected on the basis of the presence or absence of cirrhosis, the degree of hepatic 
deterioration and the number and size of tumour nodules (Colombo, 2001). 
 
The woodchuck model has been useful in the discovery and development of antiviral drugs 
and the testing of novel forms of immunotherapy (Tennant et al., 2008).  Interferon alpha 
was previously the only available therapy for the treatment of hepatitis B infection but has 
since been joined by other interferons (immune modulators) and nucleoside analogues 
(viral polymerase inhibitors) (Malik & Lee, 2000; Mangia et al., 2008).  Interferons (IFNs) 
are species-specific proteins found in vertebrates which activate a number of signalling 
pathways when bound to the IFN alpha receptor (Wieland et al., 2000; Bekisz et al., 2004), 
thus terminating viral replication (Wong et al., 1993).  Robek et al. found that IFN alpha 
requires the proteasome to mediate its antiviral effect (Robek et al., 2002).  The inhibition 
of proteasome activity by HBx has been previously discussed and this may have great 
implications in IFN treatment. 
 
Nucleoside analogues, such as lamivudine, entecavir and adefovir mainly target HBV 
polymerase thus inhibiting virus replication which could delay the onset of virus-
associated cancer (Thomas et al., 2003).  Lamivudine enters cells and is phosphorylated 
stepwise to its triphosphate metabolite where it acts as a strong inhibitor of HBV DNA 
polymerase (Rosenberg & Dienstag, 1999; Cheng, 2001).  It is then incorporated at the 
HBV DNA terminus, inhibits HBV DNA synthesis, thus preventing HBV DNA elongation 
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(Cheng, 2001).   Lamivudine has been reported to have a high incidence of resistance, as 
viral breakthrough occurred in some patients (Lai, 2003; Keeffe et al., 2008).  Resistance 
was reported in 66 % of patients on lamivudine treatment after four years (Mangia et al., 
2008). 
 
Surgical resection and liver transplant have been identified as two curative treatments for 
HCC (Pang et al., 2006).  This unfortunately applies to a small percentage of patients only, 
whose tumours are identified early.  On the other hand, systemic chemotherapy is widely 
used to treat inoperable HCC but has been shown to have a very low response rate 
(Colombo, 2001).  Gene therapy, such as RNA interference, may offer new hope to 
patients with untreatable HCC (Cheng et al., 2007; Wu et al., 2007). 
 
1.7 AIM OF RESEARCH PROJECT 
 
Monoclonal antibodies have a wide variety of applications such as their potential use in 
therapeutics (Seeger & Mason, 2000); their use in the analysis of the genetic complexities 
of antigens (Howard et al., 1979), but the aim of this research is to use them in the 
development of a diagnostic ELISA for the hepatitis B virus X protein.   
 
HCC is a very aggressive cancer, especially in sub-Saharan Africa, where most people 
presenting with symptoms usually die within three months (Mendy & Walton, 2009).  
Hence clinical practice requires the continuous development of sensitive and rapid 
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diagnostic assays for HCC (Valerie et al., 2009).  Early detection would allow for a better 
prognosis for the identified patient. 
 
Detecting alpha fetoprotein has been one of the ways of surveying HCC, especially in 
cirrhotic patients, but has been shown to be insensitive for the early detection of HCC 
(Marrero & Lok, 2004).  The role of other markers such as alpha-1-acid glycoprotein 
(AAG), glypican 3, golgi protein 73 (GP73) and desgamma carboxyprothrombin (DCP) 
has also been investigated in the diagnosis of HCC (Marrero & Lok, 2004; Bachtiar et al., 
2009).  These markers were found to lack at least some of the criteria required for an ideal 
marker of HCC, such as specificity, sensitivity, reproducibility and being inexpensive 
(Marrero & Lok, 2004; Mangia et al., 2008).  The markers would have to be used in 
various combinations for the accurate diagnosis of HCC. 
 
HBx is a good marker as it is not found in the human body, unlike other markers, unless 
HBV infection has occurred.  Its concentration in serum also been observed to increase as 
the patient progresses from chronic hepatitis to HCC (Hwang et al., 2003).  Thus, not only 
is it a good marker for diagnosis but for HCC prognosis as well.  
 
At present, no standard, large-scale routine laboratory assays are available for the 
quantitative determination of serum HBxAg content (Pál et al., 2005).  ELISAs are 
currently ranked amongst the most sensitive laboratory methods which allow for the rapid, 
easy, reliable and accurate detection of both antigens and antibodies (Tsitsilonis et al., 
2004).  Specifically, Sandwich ELISAs have been used in a variety of applications and are 
generally used for large-scale routine laboratory measurements of a number of other 
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antigens (Salgame et al., 1997; Pál et al., 2005).  Typically the design of Sandwich 
ELISAs entails the use of two monoclonal antibodies that differ in epitope specificity (i.e. 
recognise different epitopes). This however is not critical as a Sandwich ELISA may be 
designed with two mAbs that recognise the same epitope on the condition that they do not 
interfere with each other.  In this research project the Sandwich ELISA was developed 
using the latter approach. 
 
To our knowledge, there is currently no commercially available ELISA kit available for the 
assay of the HBx protein.  Therefore our aim was to develop a new detection system for 
epitopes on the HBx protein. 
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Chapter 2: MATERIALS AND METHODS 
 
2.1 HBx preparation and purification 
  
Recombinant 6xHis-HBx protein preparation and purification was carried out following 
the method in Capovilla (2003).  Recombinant pEt15B clones were transformed into E. 
coli strain BL21 and transformants selected on agar plates containing 100 µg/ml ampicillin 
and 35 µg/ml chloramphenicol.  One colony of BL21/PE15X was inoculated in 50 ml 
Luria-Bertani (LB) Broth (Appendix B1.) containing 50 µl ampicillin and incubated 
overnight at 37 ºC.  This culture was divided in two 25 ml aliquots and each added to 375 
ml fresh LB broth containing 350 µl ampicillin.  The culture was agitated at 37 ºC for 
approximately 1 hour 30 minutes to stimulate log phase growth, where after it was induced 
with 1 ml of a 200 mg/ml isopropyl-β-D-thiogalactoside (IPTG, Roche Diagnostics) stock 
solution in 50 % ethanol for 4 hours at 37 ºC with vigorous agitation.  Induced cells were 
collected by centrifugation at 3000 rpm for 5 minutes. 
 
The supernatant was discarded and the pellet re-suspended in 100 ml lysis buffer 
(Appendix B1.).  Suspensions were snap-frozen and thawed in a water bath at 37 ºC.  
While on ice, the cell suspensions were sonicated gently (5 cycles: 30 second pulse, 30 
second break).  The lysate was then centrifuged at 8000 rpm for 10 minutes and the 
supernatant discarded.  Pellet was re-suspended in 10 – 15 ml re-suspension buffer 
(Appendix B1.) which contained an 8M concentration of urea.  The mixture was then 
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centrifuged at 8000 rpm for 10 minutes and the supernatant collected for affinity 
purification 
 
Protein purification was effected by affinity binding of tagged histidines for Ni
++
 which 
had been chelated to cross-linked sepharose 6 B (Sigma).  The steps involved in HBx 
purification are diagrammatically illustrated overleaf (Figure 2.1). 
 
2.2 Immunisation of Balb/c Mice 
 
2.2.1 Animal Ethics Clearance 
 
The applicable AEC number was 2005/14/3. 
 
2.2.2 Synopsis of procedure 
 
Recombinant 6xHis-HBx derivatives coupled to bovine serum albumin (BSA) using 
benzidine, gluteraldehyde and carbodiimide (Coligan et al., 1992) were obtained from Dr 
Wolfgang Prinz.  (Coupling of poly-His-HBx was considered necessary to increase the 
immunogenicity of HBx).   
 
For the primary immunisation, Balb/c mice were injected subcutaneously (s.c.) in an 
emulsion of coupled HBx-derivative in phosphate buffered saline (PBS)/Freund‟s 
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Figure 2.1: Flow diagram: Purification of HBx.  All purification steps were carried out at room temperature.  His-tagged protein can 
be eluted at concentrations of 500 mM and above of imidazole.  Subsequent to purification, Product E1 (purified HBx from the first 
elution) was used in Western Blotting and Product E2 (purified HBx from the second elution) was used in ELISAs.  Dialysis was 
performed to concentrate the protein.  Purified 6xHis-HBx was then electrophoresed using SDS-PAGE to determine the presence of the 
protein, followed by densitometry to determine the protein‟s concentration. 
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complete adjuvant (400 μg per mouse). A booster of the same amount with Freund‟s 
incomplete adjuvant was administered 4 weeks later (also s.c). The final booster in PBS 
was administered intraperitonially 3 weeks after the 1
st
 booster.  Mice were sacrificed 5 
days later, with the spleen providing the cells for fusion. 
 
2.3 Cell Culture 
 
Hybridoma cells were maintained in culture in RPMI (Appendix B2.) supplemented with 
10 % heat-inactivated foetal calf serum (FCS, Delta Bioproducts).  In the case of a cell 
fusion, medium was further supplemented with the selective medium, HAT (hypoxanthine-
aminopterin-thymidine) (Appendix B2.) and cells were maintained in this medium for 2 
weeks.  Medium lacking aminopterin (RPMI/10 % FCS, HT) (Appendix B2.) was then 
substituted for another week.  Incubation occurred in a 37 °C/5 % CO2 incubator at 95 % 
relative humidity. 
 
2.3.1 Cell fusion 
 
Myeloma cell lines used in the fusions were either the Sp2/0-Ag14 (Shulman et al, 1978) 
or the P3-X63-Ag8.653 (Kearney et al, 1979) line.   To ensure that myeloma cells were in 
the log phase of growth, cells were diluted 1 in 5 with RPMI/10 % FCS two days prior to 
their use in the cell fusion technique.  
 
To obtain splenocytes, a spleen, obtained from an immunised Balb/c mouse, was disrupted 
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by gentle agitation through a stainless steel wire mesh.  The cell suspension was then 
transferred to a sterile centrifuge tube, topped up to 30 ml with RPMI and centrifuged in a 
Beckman TJ-6 centrifuge for 10 minutes at 1000 rpm.  Supernatant liquid was then 
discarded and 5 ml erythrocyte lysis buffer (0.14 M NH4Cl) was then added to the pellet.  
Pellet was dislodged by gentle flicking and allowed to stand for approximately 5 minutes.  
Forty millilitres RPMI was then added to remove lysis buffer and the cell suspension was 
re-centrifuged for 10 minutes at 1000 rpm.  The supernatant was discarded and washed 
once with 40 ml RPMI.  The splenocyte pellet was then re-suspended in 20 ml RPMI/10 % 
FCS and a trypan blue exclusion cell count was performed using a haemocytometer 
(Neubauer, Germany).  “Feeder cells” were obtained in the same way as above, using a 
spleen from an unimmunised mouse.  
 
Log-phase myeloma cells were washed in RPMI and centrifuged for 10 minutes at 1000 
rpm.  They were re-suspended in 20 ml RPMI/10% FCS for a cell count.  Cell count was 
performed as above.  Following the cell counts, the splenocytes (from an unimmunised 
mouse) and myelomas were diluted appropriately, and mixed such that their ratio was 5:1, 
respectively.  The cell mixture was centrifuged for 10 minutes at 1000 rpm and the 
supernatant discarded.  
 
Cell fusion took place at 37 °C.  One millilitre of polyethylene glycol (50 % PEG 1500, 
Roche) was added dropwise to the pellet with gentle shaking during 1 minute.  One 
millilitre of RPMI was then added and the mixture allowed to stand for 1 minute.  Then 2 
ml of RPMI were added and the cell suspension was allowed to stand for 2 minutes.  The 
sequence of adding 2 ml aliquots of RPMI at 2 minute intervals was repeated 3 times.  
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Thereafter, the cell suspension was topped up to 30 ml with RPMI/10% FCS and 
centrifuged for 10 minutes at 1000 rpm.  The supernatant was discarded and the cell pellet 
re-suspended in “selection medium” (RPMI/10 % FCS, HAT).  The “feeder cell” pellet 
was also re-suspended in the “selection medium” and added to the fused cell mixture such 
that the ratio of fused splenocytes to “feeders” was 1:1. 
 
Seven drops (approximately 0.5 ml) of the mixed cell suspension, containing 3 – 5 x 105 
fused splenocytes and an equal amount of “feeders”, were added to each well of a 48-well 
tissue culture plate.  Plates were then placed in a 37 °C/5 % CO2 incubator at 95 % relative 
humidity and monitored for 1 to 2 weeks by observing medium colour change, as well as 
microscopic examination.  Wells that were positive for growth (clones of hybridomas) 
were tested for HBx recognition by Indirect ELISA and Western Blotting 
(Immunoblotting). 
  
2.3.2 “Limiting dilution” of anti-HBx positive cell cultures 
 
This was performed by the standard methodology (Liddell & Cryer, 1991). Briefly, the 
selected hybridomas were plated out into 48-well plates at an average density of 0.5 cells 
per well, together with approximately 500 000 “feeder” cells obtained from spleens of 
unimmunised mice.  Cells were cultured in RPMI/10 % FCS containing OPI (oxaloacetate-
pyruvate-insulin) (Harlow & Lane, 1988) (Appendix B2.).  Plates were incubated under the 
same conditions as previously mentioned for approximately 7 to 14 days.  Wells that had 
turned yellow in colour and were positive for clonal growth were then tested for anti-HBx  
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antibody production by Indirect ELISA and Western blotting (Immunoblotting). 
 
To ensure monoclonality, the “limiting dilution” procedure was repeated twice. 
 
2.4 Electrophoresis and Blotting techniques 
 
2.4.1 Sodium dodecyl sulphate Polyacrylamide Gel Electrophoresis (SDS-
PAGE) 
 
Protein samples were separated using one-dimensional SDS-PAGE, employing the mini-
gel system (Hoefer), with a 4 % stacking gel and 15 % running gel (Appendix B3.).  
Electrophoresis was carried out at a constant 10 mA per gel thorough the stacking gel and 
15 mA per gel through the running gel for approximately 2 ½ hours.  Gels were either 
stained in Coomassie Brilliant Blue R-250 (Merck, Appendix B3.) overnight then 
destained (Destaining solution I and II, Appendix B3.), or subjected to Western blotting.   
 
In some cases where sensitivity was imperative, silver staining was used.  Gel was fixed by 
rocking in Solution A (Appendix B3.) for one hour.  The solution was discarded and the 
gel washed 3 times with 50 % ethanol (for 20 minutes).  The gel was treated in Solution B 
(Appendix B3.) for 1 minute and the solution then discarded.  MilliQ water was used to 
wash the gel 3 times (20 seconds each) then stained in Solution C (Appendix B3.) for 30 
minutes.  The gel was removed from the solution and washed in MilliQ water as above.  
The gel was then developed in Solution D (Appendix B3.) until bands of interest were 
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observed.  The reaction was stopped by washing the gel in Solution E (Appendix B3.) for 
20 minutes, followed by gentle washing in a large volume of distilled water for 30 to 60 
minutes.  The image was captured on the Gel-Doc system and analysed.  
 
2.4.2 Western Blotting 
 
Proteins were transferred onto a polyvinylidene fluoride (PVDF) membrane (Immobilon 
Millipore) using the small transfer unit (TE 22, Hoefer).  The stacking gel from the SDS-
PAGE gel was discarded and the running gel equilibrated for up to 5 minutes in transfer 
buffer (Appendix B4.).  The PVDF membrane was initially soaked in 100 % methanol for 
a few seconds then equilibrated in transfer buffer for approximately 15 minutes.  Sponges 
and filter paper to be used were also equilibrated prior to assembly of the sandwich 
cassette assembled.  Transfer was effected overnight at a constant voltage of 14V for a 
maximum of 16 hours. 
 
2.5 Immunoassay 
 
2.5.1 Immunoblot 
 
Following transfer, the PVDF membrane was cut into strips corresponding to the lanes on 
the SDS-PAGE gel.  Membrane strips were then incubated in a protein blocking solution 
(Appendix B4.) for 1 hour at room temperature with gentle agitation.  The membrane strips 
Materials and Methods  35 
 
were then washed 3 times (5 minutes each) in washing solution (Appendix B4.) and then 
incubated in various dilutions of clonal supernatant solution for 2 hours at room 
temperature with gentle agitation.  After washing as described previously, membrane strips 
were incubated in a 1 in 1000 dilution of secondary antibody (HRP(horseradish peroxidase 
)-linked anti-mouse Ig, DAKO) in blocking solution.  Strips were then washed again for 15 
minutes before being exposed to freshly prepared substrate (visualization) solution 
(Appendix B4.). 
 
2.5.2 Visualisation by Chemiluminescence 
 
Chemiluminescence involves the detection of horseradish peroxidase, an enzyme that 
catalyses the oxidation of luminol (substrate) using hydrogen peroxide (oxidizing agent), 
through the production of light (Harper & Murphy, 1991).  This enzyme is conjugated onto 
the secondary antibody and the light emitted can be imaged on photographic film and used 
to identify and quantitate the protein of interest (Bronstein et al, 1992).   
 
A kit substrate mixture (Pierce) was used.  Exposure was effected with an X-ray cassette 
(PL-C type, Kodak) and X-ray film (Fuji Medical).  Different exposure times (2 to 30 
minutes) were tested, until optimal signal was obtained.  Following exposure, the X-ray 
film was developed (X-ray Manual Developer & Replenisher solution, CAT # 9X23018) 
until the desired band intensity was obtained.  The X-ray film was then washed in distilled 
water, placed in fixer (X-ray Manual Fixer & Replenisher solution, CAT # 9X23013) for 
30 seconds and washed again. 
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2.6 Enzyme-linked Immunosorbent Assay (ELISA) 
 
2.6.1 Indirect ELISA 
 
Recombinant 6xHis-HBx, diluted in coating buffer (10 µg/ml, Appendix B5.), was used to 
coat a 96-well ELISA plate (NUNC “maxisorp”); 100 µl was dispensed into each well and 
incubated at 37 °C for 2 hours or overnight at room temperature.  Following incubation, 
the coating solution was discarded and the plate was washed three times with washing 
solution (Appendix B5.).  The plate was then dried by inverting it and tapping onto paper 
towel.  Possible remaining sites were blocked with the addition of 150 µl per well of 
blocking buffer (Appendix B5.) and incubated for 1 hour at room temperature with gentle 
agitation.  The blocking solution was then discarded and the plate was dried as before. 
 
One hundred microlitres clonal supernatant or RPMI/10% FCS (control) was added to 
duplicate wells together with 50 µl blocking buffer and incubated at room temperature for 
1 hour with gentle agitation.  Plates were then washed and dried as before.  Polyclonal 
rabbit anti-mouse Ig/HRP (DAKO, P 0260) was diluted 1 in 1000 PBS (Appendix B5.); 
100 µl of the horseradish peroxidase-conjugated secondary antibody solution was then 
added to each well and incubated for 1 hour at room temperature with gentle agitation.  
After washing as before, the plate was also washed once with 0.1 M citrate buffer 
(Appendix B5.) 
 
One hundred microlitres of freshly prepared substrate solution (Appendix B5.) was then
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added to each well for colour development.  Following incubation for 30 to 60 minutes, the 
reaction was stopped by the addition of 1 M sulphuric acid (100 µl per well).  Optical 
density at 490 nm was read in a BIORAD ELISA reader. 
 
2.6.2 Competitive ELISA 
 
The same methodology was employed as described in 2.6.1, with the following 
modification: instead on 100 µl of clonal supernatant of one mAb being added, 50 µl of 
two separate mAbs was added. 
 
2.6.3 Sandwich ELISA 
 
One hundred microlitres “capture” antibody was added at various dilutions (neat, 1 in 10, 1 
in 100 and 1 in 1000) to a 96-well ELISA plate (NUNC “maxisorp”) and incubated at 
room temperature overnight.  Coating solution was then discarded and the plate was 
washed with washing solution (Appendix B5.) and dried by inversion and tapping on paper 
towel.  Wells were then blocked by the addition of 150 µl of blocking buffer (Appendix 
B5.) to each well.  Blocking took place for 1 hour at room temperature with gentle 
agitation.  Blocking solution was then discarded and the plate was dried as before. 
 
One hundred micolitres of HBx in PBS (Appendix B5.), was added to each well and 
incubated for 1 hour at room temperature with gentle agitation.  After washing, as before, 
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100 µl of “detecting” antibody was then added at a concentration of 1 in 10, 1 in 100, 1 in 
1000 for 1 hour at room temperature with gentle agitation; washing and drying as before. 
 
Detection, using the rabbit anti mouse Ig/HRP and substrate solution, was performed as 
described previously in 2.6.1. 
 
2.7 Monoclonal antibody purification 
 
Antibody purification was carried out using the ammonium sulphate precipitation method 
(Liddell & Cryer, 1991), followed by an affinity gel selection procedure, as illustrated in 
Figure 2.2 overleaf:  
 
 
 
 
 
 
 
 
 
 
 
 
Materials and Methods  39 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Hybridoma supernatant 
(500ml) 
  Ni
++
-Resin 
HBx-prep in 7M 
Urea/PBS 
Incubate @ room 
temperature for 
2hrs with stirring 
Precipitate – Solid (NH4)2SO4 
added to 50 % saturation: allow 
to stand overnight Resin-Ni
++
-6xHis-HBx 
Centrifugation at  
4000 rpm for 10 mins Wash X2 with 7M 
Urea + PBS + 40 mM 
imidazole 
Pellet 
Wash X2 with 7M 
Urea +PBS + 80 mM 
imidazole 
Wash X2 with 50 % 
SAS* in PBS and spin 
down as above 
“Cleaned” Resin-Ni-6xHis-HBx 
Suction filtered Precipitate and re-
dissolve in 50 ml 0.25 
M Arginine in PBS, 
pH 7.4 
Incubate @ 37 °C with agitation 
Resin-Ni-HBx-mAb** 
Wash X2 with 50 ml 0.25 M 
Arginine in PBS, pH 7.4; suction 
filter, discarding filtrate 
 
“Cleaned” Resin-Ni-HBx-“6.1” 
antibody 
Elute mAb with 7 M urea 
in PBS Collect filtrate and dialyse 
exhaustively against distilled 
water and freeze dry 
Incubate in 7 M urea/PBS for 
2hrs @ room temp with stirring 
Materials and Methods  40 
 
Figure 2.2: Flow diagram: Monoclonal antibody purification.  A hybridoma clone was 
grown to exhaustion to obtain large amounts of monoclonal antibody for the supernatant.  
Purification steps, unless otherwise indicated, were carried out at room temperature.  Glass 
containers were used to minimise the loss of antibody due to non-specific adsorption to 
plastic surfaces.  The purified mAb sample was then electrophoresed to determine the 
presence of the antibody and its concentration was obtained by densitometry. (* SAS – 
saturated ammonium sulphate. 
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Chapter 3: RESULTS AND DISCUSSION 
 
3.1 HBx preparation and purification 
 
Products from the first (E1) and second (E2) eluates obtained during the purification 
process were electrophoresed in a 15 % SDS PAGE gel (Appendix B3.) and stained with 
Coomassie stain (Appendix B3.) (Figure 3.1).  The HBx band in each lane was found in 
the expected position of approximately 19 kDa (6xHis-HBx).  It is evident that product E1 
had contaminating proteins; using densitometry, it was found to have an HBx 
concentration of 0.68 mg/ml.  Product E2 had barely visible contamination and had an HBx 
concentration of 0.48 mg/ml, hence the routine use of this protein product when 
performing various ELISA tests.  Product E1 was routinely used in Western blots as this 
method is less sensitive than ELISAs and, therefore, requires a higher concentration of 
antigen.  Purified HBx was subsequently stored in PBS/7M urea. 
 
3.2 Generation of hybridoma cells producing anti-HBx antibodies 
 
3.2.1 The Immunogenicity of HBx 
 
The production of anti-HBx Abs is bedevilled by the poor immunogenicity of HBx.  This 
is partially due to the „physico-chemical‟ feature of the protein, its secondary and tertiary 
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Figure 3.1: Coomassie stained 15 % SDS PAGE gel.  MW: Molecular weight marker 
(116.0: β-galactosidase, 66.2: Bovine serum albumin, 45.0: Ovalbumin, 35.0: Lactate 
dehydrogenase, 25.0: REase Bsp981, β-lactoglobulin, 14.4: Lysozyme).  Lanes 1 and 2 
were loaded with product E1 and product E2, respectively. 
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structures and its highly hydrophobic amino acids, rendering it insoluble in water (Pál et 
al., 2003; Pál et al., 2005).  This has resulted in the inconsistency of results obtained when 
monitoring HBxAg expression in liver tissue (Doria et al., 1995; Park et al., 2000).  
Patients acutely infected with HBV were found to have relatively weak anti-HBx reactivity 
when compared to chronically infected patients (Abraham et al., 1989). 
 
In our study we attempted to overcome this by coupling HBx to larger carrier proteins.  
The deployment of recombinant HBx (with a 6xHis tag) on its own in immunisation 
resulted in only one usable mAb (“6.1”).  Other research groups have reported a similar 
lack of success (Park et al., 2000).  On the other hand, HBsAg has been found to display 
excellent immunogenicity (Roohi et al., 2005). 
 
The HBx protein has been reported to have a variety of antigenic determinants recognized 
by anti-HBx Abs, with a major domain in close proximity to the C-terminal of HBx 
(Stemler et al., 1990).  Pal et al. found it necessary to determine the fine epitope structure 
recognized by a mAb they had developed, for its use in immunoserological assays (Pál et 
al., 2003).  Through computer analysis and mass spectroscopy they identified three 
sequences predicted to be highly immunogenic.  These were amino acids (22 – 31), (110 – 
114) and (14 – 26).  Nonetheless, these sequences failed to be recognised by their antibody.  
Mapping of epitopes, in future, would be a useful approach in studying their relevance and 
reactivity with antibodies developed.  
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3.2.2 Cell fusion 
 
Hybridoma cells were generated using splenocytes of mice immunised with 6-His-HBx 
coupled to BSA carrier via benzidine, glutaraldehyde or carbodiimide.  This was 
considered necessary to augment the immunogenicity of the HBx protein.   
 
The “selection medium” for hybridoma growth contained the appropriate concentration of 
“HAT” (Hypoxanthine-aminopterin-thymidine).  The success of the procedure resides in 
the ability of the hybridoma cells to use the “salvage” pathway for purine and pyrimidine 
synthesis, while the de novo pathway is blocked (Campbell, 1984; Liddell & Cryer, 1991).  
(Aminopterin blocks the de novo pathway, while the salvage pathway relies on the 
presence of enzymes thymidine kinase (TK) and hypoxanthine (guanine) phosphoribosyl 
transferase (H(G)PRT).  Cells lacking these enzymes will die in “HAT” medium because 
both pathways for the production of DNA precursors are blocked.  Nearly all rodent cell 
lines employed in cell fusion are devoid of HGPRT.  Post fusion, only myeloma-
splenocyte hybrids will survive. 
 
Within 10 to 14 days post fusion, wells were examined for clonal growth.  Hybridomas, if 
present, had grown sufficiently and deemed to have secreted enough detectable antibody 
into the culture supernatant.  A typical mouse hybridoma, approximately two weeks after 
fusion, is shown in Figure 3.2 (Campbell, 1984).  Indirect ELISA was then performed to 
screen for hybridomas secreting anti-HBx Ab. 
 
Numerous fusions were performed but the results reported are of only the successful 
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Figure 3.2: A typical mouse hybridoma two weeks after fusion (Campbell, 1984). 
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fusions that continued to produce anti-HBx Abs even after cloning and sub-cloning by 
“limiting dilution”.  Up to the time of the commencement of this dissertation, we found 
four clones (additional to the previously-mentioned “6.1”) positive for anti-HBx Ab 
production (Figure 3.3).  On ELISA-testing, absorbance values ranged from 0.24 to 0.67, 
but only clonal supernatants with absorbance values above 0.50 were selected for cloning 
and sub-cloning by “limiting dilution”.  These absorbance values were compared to those 
of our previously developed mAb (termed “6.1”), which had a value in excess of 2.00.  
Only one “clonal mixture” was cloned at a time while the remaining ones were frozen 
(Appendix B2.) in liquid nitrogen to be cloned at a later stage. 
 
3.3 Cloning by “Limiting dilution” 
  
“Limiting dilution” aims to isolate hybridomas capable of synthesizing and secreting the 
mAb of choice from all other irrelevant hybridomas.  Cloning involves the selected growth 
of cell colonies until it can be adduced that a colony has been derived from a single cell.  
Progeny cells are then said to be monoclonal.  mAbs derived from such cells exhibit 
reactivity with a single determinant on an antigen (Liddell & Cryer, 1991).   
 
Approximately, 10 to 14 days post cloning, clonal supernatants that had turned yellow in 
colour were examined for clonal growth.  Just as with the cell fusion, these hybridomas 
had grown sufficiently and considered to have secreted enough detectable antibody into the 
culture supernatant.  Clonal supernatants were then subjected to a screening process, a flow 
diagram of which is shown in Figure 3.4. 
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Figure 3.3: Indirect ELISA following fusion.  Absorbance values of clonal supernatants 
(labelled 1 to 26) were compared to “6.1” (positive control), four of which had absorbance 
values greater than 0.50.  Clonal supernatants were utilized undiluted and clonal 
supernatant “6.1” at a 1/100 dilution. 
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Figure 3.4: Flow diagram – Screening for anti-HBx antibodies in culture 
supernatants.  A positive result in the Indirect ELISA was deemed to pertain when the 
culture supernatant had an absorbance of 0.50 and above.  A negative result was deemed to 
pertain when the absorbance was less than 0.50. 
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3.3.1 Screening of anti-HBx Abs in culture supernatants by Indirect ELISA 
 
Clonal supernatants were tested for anti-HBx Ab production by the Indirect ELISA 
method.  Absorbance values of clonal supernatants from a “successful” “limiting dilution” 
are shown in Figure 3.5.  The culture wells corresponding to absorbance values of ± 2.00 
were expanded and subjected to a second “limiting dilution”. 
 
A typical decrease of absorbance values after initial testing by Indirect ELISA is shown in 
Figure 3.6 a and 3.6 b.  Chromosomal loss may occur in the early stages of cloning, thus 
possibly causing a loss of immunoglobulin secretion (Liddell & Cryer, 1991).  „Maxi-
producers‟ are referred to as hybrids that produce a high percentage of antibodies as 
compared to „mini-producers‟.  „Maxi-producers‟ are more likely to die after a number of 
generations (Mayer & Walker, 1987).  Thus, it is advisable to maintain the parent cell line 
in culture while cloning and sub-cloning.   
 
It is generally maintained that two “limiting dilutions” suffice to produce a “fully 
monoclonal antibody producing hybridoma” (Campbell, 1984).  Clonal supernatants 
shown in Figure 3.5 were pooled and sub-cloned by a second “limiting dilution”.  
Absorbance values of clonal supernatants following the second “limiting dilution” are 
shown in Figure 3.7.  Twenty seven supernatants, out of a total of thirty six tested, had 
absorbance values above 0.50.  Absorbance values close to a value of 2.00 or above 
compared well with our positive control (“6.1”).  Pooled clonal supernatants from the first
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Figure 3.5: Indirect ELISA following cloning by “limiting dilution”.  Clonal 
supernatants were compared to “6.1” (positive control), four of which had absorbance 
values greater than 0.50.  Clonal supernatants were utilized undiluted and clonal 
supernatant “6.1” at a 1/100 dilution.  
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Figure 3.6: a) An example of an Indirect ELISA of clonal supernatants 22 days after 
fusion.  All supernatants had absorbance values greater than 0.50.  (Supernatants were not 
from the same fusion as the ones in Figure 3.3).  Clonal supernatants were utilized 
undiluted.  Clonal supernatant “6.1” was used as a positive control at a 1/1000 dilution. 
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b) – An example of an Indirect ELISA of clonal supernatants 29 days after fusion.  
All supernatants had absorbance values below 0.50.  Clonal supernatants were utilized 
undiluted.  Clonal supernatant “6.1” was used as a positive control at a 1/10 dilution. 
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Figure 3.7: Indirect ELISA following sub-cloning by “limiting dilution”.  Twenty 
seven samples had absorbance values greater than 0.50, with twenty* having absorbance 
values close to 2.00.  Pooled sample: clonal supernatants from the first “limiting dilution” 
that had absorbance values greater than 0.50 (supernatants 6, 10, 13 and 15 in Figure 3.5).  
For ELISAs and Immunoblotting, clonal supernatants and the pooled sample were utilized 
undiluted. 
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“limiting dilution” were also tested along with second “limiting dilution” supernatants; the 
pooled sample had a comparable absorbance value. 
 
One of the criteria in this research project was that mAbs produced had to give a positive 
result in both the Indirect ELISA and in Immunoblotting.  Characterisation of the mAbs 
could then take place once this had been established.  
 
3.3.2 Screening of anti-HBx Abs in culture supernatant by Immunoblotting 
 
Clonal supernatants that were positive and had high absorbance values when tested by 
Indirect ELISA were subjected to Immunoblotting. 
 
The pooled sample of clonal supernatants from the first “limiting dilution” was tested for 
its ability to bind to HBx fixed on PVDF membrane.  At a dilution of 1/10, the pooled 
hybridoma supernatant sample failed to show reactivity with HBx (Figure 3.8 a).  This 
remained so, even after a thirty minute exposure.   
 
Our previously developed mAb (“6.1”) and the commercial anti-HBx Ab were used as 
positive controls (Figure 3.8 b, 3.8 c and 3.8 d).  A strong signal was observed from the 
commercial anti-HBx Ab at a 1/5000 dilution after five minutes and our mAb “6.1” 
showed reactivity after twenty minutes.  Not all the bands of the protein marker were 
clearly visible on the blot after development but bands representing 6xHis-HBx indicated 
on Figures 3.8 c and 3.8 d correlate with the position of HBx on a Coomassie stained gel in
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Figure 3.8: a) Immunoblot of pooled hybridoma supernatants. MW (Molecular 
weight): IgG protein marker.  Lane 1 was loaded with HBx (0.68 mg/ml) and treated with a 
1/10 dilution of a pooled hybridoma sample.  Exposure time for signal development was 
thirty minutes. 
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b)  Immunoblot of the “6.1” supernatant.  MW: IgG protein marker.  Lane 1 was loaded 
with HBx (0.68 mg/ml) and treated with a 1/100 dilution of the clonal supernatant, “6.1”.  
Exposure time for signal development was thirty minutes. 
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c)  Immunoblot of the “6.1” supernatant.  MW: IgG protein marker.  Lane 1 was loaded 
with HBx (0.68 mg/ml) and treated with a 1/50 dilution of the clonal supernatant, “6.1”.  
Exposure time for signal development was ten minutes. 
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d)  Immunoblot of the commercial HBV anti-HBx antibody.   MW: IgG protein marker.  
Lane 1 was loaded with HBx (0.68 mg/ml) and treated with a 1/5000 dilution (of a 1 
mg/ml stock solution) of the commercial HBV anti-HBx Ab.  Exposure time for 
development of signal was five minutes. 
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relation to the protein marker (Figure 3.1). 
 
[One band was observed in the immunoblot of the clonal supernatant, “6.1” (Figure 3.8 b) 
but did not correspond to the approximate molecular weight of 6xHis-HBx (~ 19 kDa).  
The band was found below 19 kDa and suggests a breakdown product.  A similar result 
was observed in an immunoblot of clonal supernatant “6.1” from a separate experiment 
(Figure 3.8 c).  In this blot both the ~ 19 kDa band and the suggested breakdown product 
were observed.  Two bands were observed in the immunoblot with the commercial anti-
HBx Ab (Figure 3.8 d).  Even at a 1/10 000 dilution additional bands were still observed 
(data not shown).  Bands found below the position of HBx suggest HBx breakdown 
products, while the band above ~ 19 kDa suggests a dimer of the 17 kDa HBx protein (~ 
36 kDa). 
 
Our findings can be explained by results obtained by Feitelson & Clayton (Feitelson & 
Clayton, 1990).  When conducting a study to screen for HBxAg reactive material in HBV-
infected individuals, they identified an approximately 17 kDa and an approximately 13 
kDa band in some patients‟ sera (Feitelson & Clayton, 1990).  They found that cleavage of 
the 17 kDa HBxAg may result in the appearance of the 13 kDa HBxAg.  This has also 
been reported in other findings (McLachlan, 1991); cleavage of HBc antigen gave rise to 
HBe antigen (Feitelson & Clayton, 1990).  The 17 kDa HBxAg was, however, the 
dominant polypeptide.  Feitelson & Clayton also reported on the presence of an 
approximately 36 kDa polypeptide species in several sera, which it claimed to be 
consistent with a dimer of the 17 kDa HBxAg (Feitelson & Clayton, 1990). 
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Some of our blots failed to yield a visible HBx protein band.  One reason may be that 
antigens electrophoresed in gels containing SDS will be denatured, leading to failure to 
recognize their respective epitopes (Campbell, 1984)].   
 
Since the pooled sample only yielded a positive result in the Indirect ELISA, “6.1” and the 
commercial anti-HBx antibody were characterised and paired in the Sandwich ELISA. 
 
3.4 Characterisation of monoclonal antibodies 
 
Procedures used in the characterisation of monoclonal antibodies vary widely with their 
intended use.  It is highly unlikely that a single mAb developed will have all the required 
characteristics; therefore it is advisable to screen a large panel of mAbs (Campbell, 1984). 
 
In this study, antibodies were characterised according to their binding affinities and 
relative epitope specificity.  These characteristics are important in the application of the 
antibody, even more so when more than one mAb is used in the same assay.  In the 
development of a Sandwich ELISA, it is imperative to obtain mAbs with non-overlapping 
epitope specificity. 
 
3.4.1 Relative binding affinity 
 
Affinity has been described as “the strength of interaction between an antibody and an 
antigen in a given system” (Liddell & Cryer, 1991).  Antibodies with high binding 
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affinities are essential in immunoassays as they have to endure vigorous washing 
procedures and still remain attached to the target antigen/antibody.  Clonal supernatants 
eliciting a strong positive result whilst having a low antibody level are likely to have a high 
binding affinity (Campbell, 1984). 
 
Determination of binding affinity was carried out using the Indirect ELISA (See Figure 
3.7).  The high absorbance obtained in the Indirect ELISA suggests that the respective 
mAbs were able to bind to the HBx protein with a high binding affinity.  Absorbance 
values obtained compared well with those of the commercial anti-HBx Ab (Figure 3.9) and 
those of serial dilutions of our developed Ab (“6.1”), shown in Figure 3.10.   
 
3.4.2 Relative epitope specificity 
 
Relative epitope specificity is an important aspect of epitope analysis.  Its relevance comes 
into play when determining the intended use of the monoclonal antibody.  For instance, 
when dealing with more than one mAb in an assay, it is very important to take the 
combination of the mAbs to be used into consideration, so as to reduce cross-reactivity.  
Determination of the relative epitope specificity of the mAbs was carried out using the 
Competitive ELISA, a necessary procedure, in order to determine whether antibodies are 
directed at the same or different epitopes.   
 
The results obtained from a competitive ELISA of our previously developed mAb (“6.1”) 
and the commercial anti-HBx Ab are shown in Figure 3.11 a.  Our previously developed  
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Figure 3.9:  Absorbance values of the commercial anti-HBx antibody at increasing 
dilutions.  Quantitative analysis was carried out using the Indirect ELISA.  “6.1” was 
obtained from a clonal supernatant and deployed undiluted. 
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Figure 3.10:  Serial dilutions of the developed antibody “6.1”.  Quantitative analysis 
was carried out using the Indirect ELISA.  The HBV X protein had a concentration of 0.48 
mg/ml. 
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Figure 3.11: a) Competitive ELISA of “6.1” and CA to assess relative epitope 
specificity.  6.1: monoclonal antibody “6.1” and CA: commercial anti-HBx Ab.  When 
antibodies were added together, 50 µl of each mAb was added, making a total of 100 µl 
primary antibody added, the same total volume used when tested singly.  “6.1” was used 
undiluted and the commercial antibody was used at a 1/1000 dilution of a 1 mg/ml stock 
solution.
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mAb (“6.1”) was also competed with clonal supernatants from the first “limiting dilution” 
of a subsequent fusion (6, 10, 13 and 15), the results being shown in Figure 3.11 b and 
Figures C1 to C9 (Appendix C).  The absorbance values of some combined mAbs were 
similar to when they were added individually.  This was true for “6.1” and CA 
(commercial anti-HBx Ab), “mAb1” & “mAb2”, “mAb2” & “mAb4”, “mAb3” & 
“mAb4”, “mAb1” & “6.1” and “mAb1” & “mAb4” (Figures 3.11 a, C1, C2, C3, C4 and 
C9).  These results were indicative of competition between the respective antibodies.  This 
then translates into them sharing the same epitope and/or their binding sites too close 
together for them to bind independently of each other. 
 
On the other hand, the absorbance values for the combination of “mAb4” & “6.1”, 
“mAb2” & “6.1”, “mAb2” & “mAb3”, “mAb3” & “6.1” and “mAb1” & “mAb3” were 
greater than of those added individually (Figure 3.11 b and Figures C5, C6, C7 and C8  
(Appendix C)).  According to Kuffner et al. (Kuffner et al., 1988), this is indicative of 
absence of competition between the antibodies, showing their binding to different epitopes 
(Kuffner et al., 1988); however a degree of overlapping epitope specificity may be 
possible.   
 
Other methods used to identify whether mAbs recognize the same epitope on an antigen 
include FPLC (Fast Protein Liquid Chromatography) Superose 12 gel filtration (Karande et 
al., 1987), a competition assay where the binding of a labelled antibody to an antigen is 
blocked by a second antibody (Stähli et al., 1983) and a previously developed screening 
ELISA (Alsenz & Loos, 1988).  The screening assay is rapid, simple and requires no 
labelled antigen or antibody.  The antigen is pre-incubated with a mAb and then added to a  
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Figure 3.11: b) Competitive ELISA of “6.1” and mAb4 to assess relative epitope 
specificity.  6.1: monoclonal antibody “6.1” and “mAb4”: clonal supernatant from the first 
“limiting dilution”.  When antibodies were added together, 50 µl of each mAb was added, 
making a total of 100 µl primary antibody added, the same total volume used when tested 
singly.  Both “mAb4” and “6.1” were used undiluted.  
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microtitre plate coated with a second mAb.  The principle behind the screening ELISA is 
based on the theory that the antigen pre-incubated with a mAb will not be recognized by a 
„capture‟ antibody if the first mAb has the same epitope specificity as the second mAb 
added. 
 
Not all the clonal supernatants were found having the same epitope specificity.  Some 
bound to the same epitope while others bound to mutually exclusive epitopes.  For the 
purpose of this research, the binding of antibodies to different epitopes was not crucial, as 
long as their combination allowed for efficient functioning in a Sandwich ELISA. 
  
3.5 Antibody purification 
 
Purification of antibodies was necessary to rid the clonal supernatants of contaminating γ-
globulins from the foetal calf serum so as to allow for optimal binding of HBX-specific 
mAb to the ELISA plate in the Sandwich ELISA.   
 
The first step in antibody purification was precipitation by ammonium sulphate (AS) 
precipitation.  This method was chosen because of its general applicability and that it is far 
less expensive than Protein A purification (for mouse and human IgG).  Up to the time of 
commencing this report, only our previously developed mAb (“6.1”) was purified, by the 
method specified in the Materials and Methods (section 2.7).  It was paired with the 
commercial anti-HBx Ab in the Sandwich ELISA. 
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3.6 Design of the Sandwich ELISA 
 
Two antibodies are necessary for a Sandwich ELISA, one as the „capture‟ Ab and the other 
as the „detecting‟ Ab.  The „capture‟ Ab, which may or may not be monoclonal, is bound to 
the solid phase, and then antigen is added followed by the „detecting‟ Ab which may or 
may not bind to the antigen on another site (Campbell, 1984).  In this study, both “6.1” and 
the commercial anti-HBx Ab were tested as the „capture‟ or „detecting‟ Ab.  Results of 
which are discussed in section 3.6.1. 
 
3.6.1 Optimisation of the Sandwich ELISA 
 
The following parameters were tested in the Sandwich ELISA: sequence of the „capture‟ 
and „detecting‟ Ab, blocking buffer, coating buffer, concentrations of the HBV X protein, 
and the concentrations of the secondary antibody and substrate. 
 
Development of this type of ELISA requires the careful selection of a complementary pair 
of mAbs.  A schematic representation of this assay is shown in Figure 3.12.  Some mAbs 
have been reported to function better as „detecting‟ antibodies than as „capture‟ antibodies 
(Kuffner et al., 1988).  This could be caused by partial “denaturation” of antibodies when 
adsorbed to the solid matrix (microtitre plate), rendering them ineffective for antigen 
capture (Kuffner et al., 1988).   
 
When the commercial anti-HBx Ab was used as the „capture‟ Ab, “6.1” worked well as the
Results and Discussion  70 
 
 
 
 
 
 
 
 
 
Figure 3.12: A schematic diagram of a Sandwich ELISA.   
(newenglandbiolabs.de/…/cst_elisa_gross.jpg)
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„detecting‟ Ab (Figure 3.13 a).  A good result was also obtained when the commercial 
anti-HBx Ab was the antibody in both positions.  When the roles of these two antibodies 
were reversed, the result was less satisfactory (Figure 3.13 b).  Obtaining „capture‟ and 
„detecting‟ antibodies that work well together allows for the efficient binding and 
quantification of the target antigen.   
 
The coating buffer used to prepare the „capture‟ Ab for coating may also have an effect.  
Secondary antibody has the ability to bind to both the „capture‟ and „detecting‟ Abs but in 
this assay, through the careful selection of buffer, it should only detect the „detecting‟ 
antibody and not the „capture‟ Ab.  Therefore, the absorbance obtained should only reflect 
the amount of „detecting‟ antibody bound to antigen and not the amount of „capture‟ Ab.   
 
The absorbance values obtained when phosphate buffered saline (PBS) was used as the 
coating buffer are shown in Figure 3.14 a.  An absorbance value of approximately 1.85 
was obtained when “6.1” was added as the „detecting‟ Ab.  Likewise, when RPMI/10 % 
FCS (blank) was added instead of the „detecting‟ Ab, a similar absorbance value was 
obtained.  Hence, the secondary antibody added bound to the Fc region of the „capture‟ Ab.  
With bicarbonate as the coating buffer (Figure 3.14 b), a very low absorbance was 
obtained when RPMI/10 % FCS (blank) was added in place of the „detecting‟ Ab.  When 
“6.1” was added as the „detecting‟ Ab, a final absorbance value of greater than 1.00 was 
obtained and an absorbance values of 0.04 when RPMI/10 % FCS (blank) was added, 
indicating that the secondary antibody was detecting “6.1” and not the „capture‟ Ab.  
Bicarbonate was, therefore, chosen as the coating buffer in our Sandwich ELISA.
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Figure 3.13: a) Sandwich ELISA to select a preferred antibody for the „detecting‟ 
position.  The commercial anti-HBx Ab was used as the „capture‟ Ab at a 1/200 dilution 
(of a 1 mg/ml stock solution).  Our previously developed Ab, “6.1”, was used at a 1/100 
dilution of a 3 mg/ml stock solution.   
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b) Sandwich ELISA to select a preferred antibody for the „detecting‟ position.  Our 
previously developed Ab (“6.1”) was used as the „capture‟ Ab at a 1/100 dilution of a 3 
mg/ml stock solution.  The commercial anti-HBx Ab was deployed at a 1/200 dilution (of a 
1 mg/ml stock solution). 
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Figure 3.14: a) Sandwich ELISA with PBS used as the coating buffer.  The commercial 
antibody was used as the „capture‟ Ab at a 1/200 dilution (of a 1 mg/ml stock solution) and 
“6.1” as the „detecting‟ antibody at a 1/100 dilution of a 3 mg/ml stock solution.  The high 
absorbance value obtained for the blank showed that secondary antibody was detecting the 
„capture‟ Ab.  
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b) Sandwich ELISA with bicarbonate buffer used as the coating buffer.  The 
commercial antibody was used as the „capture‟ Ab at a 1/200 dilution (of a 1 mg/ml stock 
solution) and “6.1” as the „detecting‟ Ab at a 1/100 dilution of a 3 mg/ml stock solution.  
The low absorbance value obtained for the blank showed that secondary antibody was not 
detecting the „capture‟ Ab. 
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When using solid-phase assays, blocking of possible remaining binding sites on the 
microtitre plate (to prevent non-specific adsorption of proteins) is essential (Campbell, 
1984).  Commonly used blocking agents include BSA, non-fat milk powder and gelatine 
(Campbell, 1984).  In this study, 2 % BSA, 2 % non-fat milk powder and RPMI/10 % FCS 
were tested in determining the optimal blocking agent in the Sandwich ELISA (data not 
shown).  In all cases, BSA yielded the lowest blank absorbance values, followed by 
RPMI/10 % FCS, while 2 % non-fat milk powder gave rise to the highest blank absorbance 
values, therefore, 2 % BSA was used as the blocking agent in our Sandwich ELISA.  
 
A high blank absorbance is indicative of the secondary antibody detecting the „capture‟ Ab 
as no „detecting‟ Ab is added.  On the other hand, a low blank absorbance value indicates 
that the secondary antibody is not binding to the „capture‟ Ab. 
 
The absorbance values obtained with antigen at various dilutions are shown in Figure 3.15.  
A straight-line relationship between the absorbance and the log of the concentration is 
well-established in ELISAs.  It clearly applies in our instance.  In our Sandwich ELISA, 
HBx was used at a concentration of 0.68 mg/ml.  In our laboratory, this assay is currently 
being adapted to detect HBx in serum. 
 
The concentration of the „capture‟ Ab used in our assay was somewhat in excess of the 
putative binding capacity of the ELISA plate plastic.  The commercial anti-HBx Ab was 
used as the „capture‟ Ab, at a 1/200 dilution of a 1 mg/ml stock solution, while “6.1” was 
used at a 1/100 dilution of 3 mg/ml stock solution as the „detecting‟ Ab.  
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Figure 3.15: Sandwich ELISA with antigen at various dilutions.  The commercial 
antibody was used as the „capture‟ Ab at a 1/200 dilution of a 1 mg/ml stock solution and 
the previously developed antibody, “6.1”, was used as the „detecting‟ Ab at a 1/100 
dilution (of a 3 mg/ml stock solution).  Graph shows „best fit‟ of experimental points.
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The concentration of the secondary antibody and substrate were kept standard, following 
the protocol for the Indirect ELISA (see Materials and Methods, 2.6.1). 
 
Coupling the „detecting‟ antibody to biotin has been reported to produce an enhanced 
signal as compared to the simpler HRP-labelled antibody method (van Gijlswijk et al., 
1996).  The „detecting‟ Ab in this study was not labelled in any way; instead a HRP-
labelled secondary antibody was employed to detect the „detecting‟ antibody.  Biotin-
avidin detection systems are also reported as being more sensitive than simple HRP 
systems.  Some researchers have also reported the use of polyclonal or multiple mAbs as 
the „capture‟ Ab (Tsitsilonis et al., 2004).  Polyclonal antibodies recognizing various 
epitopes on a particular antigen have been reported to eliminate non-specific cross-reaction 
and increase the overall sensitivity of the assay, but long-term reproducibility cannot be 
guaranteed. 
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Chapter 4: CONCLUSION 
 
We have successfully developed a Sandwich ELISA for HBx using a commercial anti-HBx 
antibody and an “in house” monoclonal antibody.  Through Indirect ELISA and 
Competitive ELISA we revealed that our mAb “6.1” and the commercial anti-HBx bound 
to HBx with a high affinity and recognizing the same or closely-related epitope/s on HBx.  
Both mAbs also showed good reactivity with HBx on immunoblots.  Our other hybridomas 
cloned by “limiting dilution” produced mAbs directed against HBx, with a binding affinity 
comparable to our mAb “6.1” (as evident on Indirect ELISA), but failed to react with HBx 
in immunoblots.  PAGE under non-denaturing conditions might prove otherwise. 
 
Since commencing this dissertation, three more monoclonal antibodies were generated in 
our laboratory.  We are planning to deploy these in a diagnostic ELISA testing for HBx in 
patient sera. 
 
We are confident of developing a Sandwich ELISA applicable to patient sera which would 
allow for the early identification of carriers at risk of developing hepatocellular carcinoma.  
Since a commercial ELISA for the detection of the HBx protein in body fluids is not, to 
our knowledge, currently available, our proposed Sandwich ELISA would be of significant 
value in the evaluation of the disease status. 
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APPENDIX A: ETHICS APPROVAL 
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APPENDIX B: SOLUTIONS AND CHEMICALS 
 
B1. HBx/Protein preparation 
 
Luria-Bertani (LB) Broth 
 10 g Tryptone 
 5 g Yeast extract 
 10 g NaCl 
o Make up to 1 litre with distilled water; 
o Autoclave; 
o Store at 4 ºC 
 
Lysis Buffer 
 20 mM PO4, pH 7.8 
 2mM β-mercaptoethanol 
 1 % Nonidet P.40 
 1mM EDTA  
 100mM KCl 
 
Re-suspension Buffer 
 20 mM PO4, pH 7.8 
 2mM β-mercaptoethanol 
 8 M Urea 
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 10 mM Imidazole 
 
Buffer A 
 20 mM Na-phosphate, pH 7.5 
 8 M Urea 
 2 mM β-mercaptoethanol 
 10 mM Imidazole 
 
Buffer B 
 20 mM Na-phosphate, pH 7.5 
 8 M Urea 
 2 mM β-mercaptoethanol 
 60 mM Imidazole 
 
Buffer C 
 20 mM Na-phosphate, pH 7.5 
 7 M Urea 
 2 mM β-mercaptoethanol 
 600 mM Imidazole 
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B2. Tissue culture 
 
RPMI 
 32.88 g 1640 RPMI (Gibco) 
 6.9 g HEPES (Sigma) 
 6.3 g NaHCO3 
 0.2 g Penicillin G (Sigma) 
 0.33 g Streptomycin (Sigma) 
  315 mg Glutamine (Sigma) 
o Dissolve gently in 3150 ml distilled water using a magnetic stirrer; 
o Sterilize by filtration through a 22 µm filter (Osmonics Inc) and two 
prefilters (Millipore Corporation); 
o Place bottles containing filtered RPMI in a 37 °C incubator overnight to 
check for sterility.  
 
RPMI/10 % FCS 
 100 ml heat-inactivated foetal calf serum 
 900 ml RPMI 
o Store at 4°C. 
 
HAT and HT stock solution 
 Purchased from GIBCO  
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OPI stock solution (100x) 
 1.5 g Oxaloacetate 
 500 mg Pyruvate 
 82 mg (2000 IU) Insulin 
o Make up to 100 ml with distilled water 
 
Freezing Medium 
 28 ml RPMI (without FCS) 
 17 ml FCS 
 5 ml DMSO 
 
B3. Sodium dodecyl sulphate Polyacrylamide Gel Electrophoresis (SDS- 
       PAGE) 
 
Monomer solution  
 60 g acrylamide 
 1.6 g bisacrylamide 
o Make up to 200 ml with distilled water; 
o Store for up to 3 months at 4°C in the dark. 
 
4 X Running gel buffer (1.5 M Tris-Cl, pH 8.8) 
 36.3 g Tris 
o Add 150ml with distilled water; 
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o Adjust pH with HCl; 
o Make up to 200 ml with distilled water; 
o Store for up to 3 months at 4°C in the dark. 
 
4 X Stacking Gel Buffer (0.5 M Tris-Cl, pH 6.8) 
 3.0 g Tris 
o Add 40 ml distilled water; 
o Adjust pH with HCl; 
o Make up to 50 ml with distilled water; 
o Store for up to 3 months at 4°C in the dark. 
 
Table 1: The ratios of mixtures for a 15 % running gel (for 4 gels) 
Mixtures  
Monomer solution 22.5 ml 
 4 X Running gel buffer 11.25 ml 
10 % SDS 450 µl 
Distilled water 10.65 ml 
Ammonium persulphate 300 µl 
TEMED* 25 µl 
* N,N,N,N – Tetramethyl-ethylenediamine 
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Table 2: The ratios of mixtures for a 4 % stacking gel (for 4 gels) 
Mixtures   
Monomer solution 4 ml 
4 X Stacking gel buffer 7.5 ml 
10 % SDS  300 µl 
Distilled water 18 ml 
Ammonium persulphate 210 µl 
TEMED* 22.5 µl 
* N,N,N,N – Tetramethyl-ethylenediamine 
 
10 % SDS 
 10 g SDS  
o Make up to 100 ml with distilled water; 
o Store for up to 6 months at room temperature. 
 
10 % Ammonium persulphate (Initiator) 
 0.1 g ammonium persulphate  
o Make up to 1.0 ml with distilled water; 
o Use fresh; do not store. 
 
2 X Loading buffer (pH 6.8) 
 2.5 ml 4 X stacking gel buffer 
 4 ml 10 % SDS 
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 2 ml glycerol or 2.3 ml 87 % glycerol 
 2.0 mg bromophenol blue 
 0.31 g dithiothreitol (DTT) 
o Make up to 10 ml with distilled water; 
o Store for up to 6 months in 0.5 ml aliquats at – 20 °C. 
 
Running buffer 
 3.03g Tris 
 14.4 glycine 
 1 g SDS  
o Make up to 1 litre with distilled water 
o Store at room temperature for up to 1 month. 
 
Coomassie stain 
 0.5 g Coomassie Blue R-250  
 250 ml isopropanol 
 100 ml acetic acid 
o Make up to 1 litre with distilled water; 
o Store at room temperature for up to 6 months. 
 
Destaining solution I 
 400 ml methanol 
 70 ml acetic acid 
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o Make up to 1 litre with distilled water; 
o Store at room temperature indefinitely. 
 
Destaining solution II 
 50 ml methanol 
 70 ml acetic acid 
o Make up to 1 litre with distilled water; 
o Store at room temperature indefinitely. 
  
Silver stain 
Solution A 
 150 ml ethanol 
 36 ml glacial acetic acid 
 150 µl 37 % formaldehyde 
o Make up to 300 ml with MilliQ water. 
 
Solution B 
 30 mg sodium thiosulfate  
o Make up to 300 ml with MilliQ water. 
 
Solution C 
 300 mg silver nitrate 
o Make up to 300 ml with MilliQ water; 
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o Make up fresh. 
 
Solution D 
 9 g sodium carbonate 
 150 µl 37 % formaldehyde 
 6 ml Solution B 
o Make up to 300 ml with MilliQ water. 
 
Solution E 
 2.8 g EDTA 
o Make up to 300 ml with MilliQ water. 
 
B4. Western/Immunoblotting 
 
Transfer buffer 
 7.58 g Tris 
 36.03 g glycine 
 2.5 g SDS 
o Measure pH (8.2 – 8.4) but do not adjust; 
o Make up to 2 litres with distilled water; 
o Add 500 ml methanol; 
o Store at 4 º C. 
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Tris buffered saline (TBS), pH 7.4 
 3.63 g Tris 
 13.5 g NaCl  
o Make up to 1400 ml with distilled water; 
o Measure and adjust pH to 7.4 with HCl; 
o Make up to 1500ml with distilled water; 
 
Protein blocking solution 
 25 g non-fat milk powder 
o Make up to 500 ml with TBS; 
o Add 5 ml of a 10 % sodium azide stock solution; 
o Store at 4 º C. 
 
Washing solution  
 1 g non-fat milk powder 
o Make up to 1 litre with TBS; 
o Add 10 ml of a 10 % sodium azide stock solution. 
 
Antibody incubation solution 
 2 g non-fat milk powder 
 1 ml of a 10 % Tween-20 stock solution 
o Make up to 200 ml with TBS; 
o Add 2 ml of a 10 % sodium azide stock solution. 
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Substrate solution  
 Kit substrate mixture (Pierce) 
 1:1 ratio of luminol and hydrogen peroxide 
o Make up fresh in a foil covered container; 
o Discard after use. 
 
B5. Enzyme-linked immunosorbent assay (ELISA) 
 
Coating buffer (pH 9.6) 
 1.59 g Na2CO3 
  2.93 g NaHCO3  
 0.05 % sodium azide  
 0.1 % Tween-20 (pH 9.6) 
o Make up to 1 litre with distilled water. 
 
Washing solution 
 0.9 % NaCl  
 0.1 % Tween-20 
o Make up to 1 litre with distilled water. 
 
Dilution/blocking buffer 
 0.05 M Tris (pH 7.4) 
 2 % Bovine serum albumin (BSA, Sigma) 
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 0.1 % Tween-20 
 0.02 % sodium azide 
o Make up to 250 ml with distilled water. 
 
Citrate buffer (0.1M, pH 5) 
 7.3 g citric acid·H2O  
 9.5 g Na2HPO4 or 
 11.8 g Na2HPO4·2H2O or 
  20 g Na2HPO4·12H2O 
o Make up to 1 litre with distilled water. 
 
Substrate solution 
 16 mg o-phenylenediamine dihydochloride (Sigma) 
o Make up to 30 ml with 0.1 M Citrate buffer; 
o Add 18 µl 30 % H2O2. 
 
Phosphate buffered saline (PBS), 10X 
 90 g NaCl 
 2.1 g KCl 
 2 g KH2PO4 
 12 g Na2H PO4  
o Make up to 1 litre with distilled water; 
o Store at room temperature.  
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APPENDIX C: FIGURES 
 
Figures C: Competitive ELISA to assess relative epitope specificity.  6.1: monoclonal 
antibody “6.1”, mAb1 – mAb4: different clonal supernatants from the first “limiting 
dilution”.  When antibodies were added together, 50 µl of each mAb was added, making a 
total of 100 µl primary antibody added, the same total volume used when tested singly. 
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